On the financial front, Rigel reported an expected total revenue of approximately $57.6 million for the fourth quarter of 2024, a substantial increase from the same period in 2023. The company's ...

SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

Rigel Pharmaceuticals Inc Lisa Rojkjaer; Executive Vice President, Chief Medical Officer; Rigel Pharmaceuticals Inc Dean Schorno; Chief Financial Officer, Executive Vice President; Rigel ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were ...

We plan to initiate the dose expansion phase of the study and provide the updated data at a medical meeting later this year. For olutasidenib, we plan to initiate a new Rigel-sponsored Phase II ...

He holds a B.S. from Yale College and an M.D. from Harvard Medical School. His academic accolades include a chief residency and a Howard Hughes postdoctoral fellowship at UCSF. Rigel’s president ...

March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical ...

Several research firms have recently issued reports on RIGL. B. Riley increased their price objective on shares of Rigel Pharmaceuticals from $17.00 to $27.00 and gave the stock a “neutral ...